NIH launches clinical trial for hospital patients, antibody research network
The National Institutes of Health has launched a global clinical trial to test a potential COVID-19 treatment that combines remdesivir with a highly concentrated antibody solution. The phase 3 trial will enroll 500 hospitalized adults who have had COVID-19 symptoms for 12 or fewer days and no serious organ dysfunction, and compare their health status after the combination treatment with participants receiving remdesivir and a placebo. The agency also announced a research network to study the immune response to COVID-19 and increase antibody testing capacity.
Related News Articles
Headline
The Food and Drug Administration yesterday announced that Olympus issued a global recall of its ViziShot 2 FLEX needles manufactured prior to May 12 following…
Headline
The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…
Headline
The Department of Health and Human Services Sept. 18 announced it will take new actions to help improve care for individuals with long COVID. They include a…
Headline
The Food and Drug Administration has identified a Class I recall for Mo-Vis BVBA R-net Joysticks due to a firmware error that causes the wheelchair to ignore…
Headline
The Centers for Disease Control and Prevention is predicting a similar combined number of peak hospitalizations from COVID-19, the flu and respiratory…
Headline
The Occupational Safety and Health Administration today announced a 60-day extension of the comment period on its proposed rule to remove the remaining…